JP2011507852A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011507852A5 JP2011507852A5 JP2010539496A JP2010539496A JP2011507852A5 JP 2011507852 A5 JP2011507852 A5 JP 2011507852A5 JP 2010539496 A JP2010539496 A JP 2010539496A JP 2010539496 A JP2010539496 A JP 2010539496A JP 2011507852 A5 JP2011507852 A5 JP 2011507852A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- binding portion
- monoclonal antibody
- isolated monoclonal
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12/005,054 US7906116B2 (en) | 2005-09-01 | 2007-12-20 | Methods for using and identifying modulators of Delta-like 4 |
| PCT/US2008/013899 WO2009085209A2 (en) | 2007-12-20 | 2008-12-19 | Methods for using and identifying modulators of delta-like 4 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011507852A JP2011507852A (ja) | 2011-03-10 |
| JP2011507852A5 true JP2011507852A5 (https=) | 2012-02-23 |
Family
ID=40524791
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010539496A Pending JP2011507852A (ja) | 2007-12-20 | 2008-12-19 | デルタ様４のモジュレーターの利用及び同定方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US7906116B2 (https=) |
| JP (1) | JP2011507852A (https=) |
| CN (1) | CN101970004A (https=) |
| CA (1) | CA2710082A1 (https=) |
| IL (1) | IL206502A0 (https=) |
| WO (1) | WO2009085209A2 (https=) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7906116B2 (en) * | 2005-09-01 | 2011-03-15 | Parkash Gill | Methods for using and identifying modulators of Delta-like 4 |
| US9567396B2 (en) * | 2006-03-07 | 2017-02-14 | Evonik Degussa Gmbh | Notch inhibition in the prevention of vein graft failure |
| EA018260B1 (ru) * | 2006-09-29 | 2013-06-28 | Онкомед Фармасьютикалз, Инк. | Антитела к дельта-подобному лиганду 4 человека и их применение |
| US20100260668A1 (en) * | 2008-04-29 | 2010-10-14 | Abbott Laboratories | Dual Variable Domain Immunoglobulins and Uses Thereof |
| BRPI0910482A2 (pt) * | 2008-04-29 | 2019-09-24 | Abbott Lab | imunoglobinas de domínio variável duplo e usos das mesmas |
| BRPI0913366A8 (pt) * | 2008-06-03 | 2017-07-11 | Abbott Lab | Imunoglobulinas de domínio variável duplo e seus usos |
| PE20100092A1 (es) * | 2008-06-03 | 2010-03-12 | Abbott Lab | Inmunoglobulina con dominio variable dual y usos de la misma |
| NZ603698A (en) | 2008-07-08 | 2014-03-28 | Abbvie Inc | Prostaglandin e2 dual variable domain immunoglobulins and uses thereof |
| MX2011005953A (es) * | 2008-12-04 | 2011-08-17 | Abbott Lab | Inmunoglobulinas de dominio variable dual y usos de las mismas. |
| UY32808A (es) * | 2009-07-29 | 2011-02-28 | Abbott Lab | Inmunoglobulinas como dominio variable dual y usos de las mismas |
| WO2011025964A2 (en) * | 2009-08-29 | 2011-03-03 | Abbott Laboratories | Therapeutic dll4 binding proteins |
| KR20120060877A (ko) | 2009-09-01 | 2012-06-12 | 아보트 러보러터리즈 | 이원 가변 도메인 면역글로불린 및 이의 용도 |
| AU2010306677B2 (en) | 2009-10-15 | 2013-05-23 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
| ES2700450T3 (es) * | 2009-10-16 | 2019-02-15 | Oncomed Pharm Inc | Combinación terapéutica y uso de anticuerpos antagonistas de DLL4 y agentes antihipertensores |
| UY32979A (es) * | 2009-10-28 | 2011-02-28 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
| EP2493497A4 (en) | 2009-11-01 | 2013-07-24 | Brigham & Womens Hospital | NOTCH INHIBITION IN THE TREATMENT AND PROPHYLAXIS OF ADIPOSITAS AND METABOLISM SYNDROME |
| CA2780221A1 (en) | 2009-11-04 | 2011-05-12 | Fabrus Llc | Methods for affinity maturation-based antibody optimization |
| CA2782299A1 (en) * | 2009-12-01 | 2011-06-09 | Oncomed Pharmaceuticals, Inc. | Methods for treating cancers comprising k-ras mutations |
| CN103037900B (zh) | 2010-02-24 | 2016-04-06 | 伊缪诺金公司 | 叶酸受体1抗体与免疫缀合物以及其用途 |
| AU2014203172B2 (en) * | 2010-02-24 | 2016-03-10 | Immunogen, Inc. | Folate Receptor 1 Antibodies and Immunoconjugates and Uses Thereof |
| BR112012021941A2 (pt) * | 2010-03-02 | 2022-02-01 | Abbvie Inc | Proteínas terapêuticas de ligação a dll4 |
| US8735546B2 (en) | 2010-08-03 | 2014-05-27 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
| PE20140229A1 (es) | 2010-08-26 | 2014-03-27 | Abbvie Inc | Inmunoglobulinas con dominio variable dual y usos de las mismas |
| US8551479B2 (en) | 2010-09-10 | 2013-10-08 | Oncomed Pharmaceuticals, Inc. | Methods for treating melanoma |
| LT3485903T (lt) | 2011-09-23 | 2023-02-27 | Mereo Biopharma 5, Inc. | Vegf/ dll4 surišantys agentai ir jų panaudojimas |
| AR089529A1 (es) | 2011-12-30 | 2014-08-27 | Abbvie Inc | Proteinas de union especificas duales dirigidas contra il-13 y/o il-17 |
| MX375673B (es) | 2012-04-02 | 2025-03-06 | Berg Llc | Ensayos basados en interrogatorios celulares y usos de los mismos. |
| KR101535341B1 (ko) | 2012-07-02 | 2015-07-13 | 한화케미칼 주식회사 | Dll4에 특이적으로 결합하는 신규한 단일클론항체 및 이의 용도 |
| US9599620B2 (en) | 2012-10-31 | 2017-03-21 | Oncomed Pharmaceuticals, Inc. | Methods and monitoring of treatment with a DLL4 antagonist |
| KR20180008921A (ko) | 2012-11-01 | 2018-01-24 | 애브비 인코포레이티드 | 항-ｖｅｇｆ／ｄｌｌ4 이원 가변 도메인 면역글로불린 및 이의 용도 |
| CN105324396A (zh) | 2013-03-15 | 2016-02-10 | 艾伯维公司 | 针对IL-1β和/或IL-17的双重特异性结合蛋白 |
| US10184010B2 (en) | 2013-07-09 | 2019-01-22 | Ablbio | Dual-targeting protein binding specifically to DLL4 and VEGF and use thereof |
| GB201312727D0 (en) * | 2013-07-16 | 2013-08-28 | Isis Innovation | Modulators |
| CA2960837A1 (en) | 2014-09-11 | 2016-03-17 | Berg Llc | Bayesian causal relationship network models for healthcare diagnosis and treatment based on patient data |
| GB201416832D0 (en) * | 2014-09-24 | 2014-11-05 | Glaxosmithkline Plc | Methods of treatment |
| WO2016070051A2 (en) | 2014-10-31 | 2016-05-06 | Oncomed Pharmaceuticals, Inc. | Combination therapy for treatment of disease |
| WO2016094881A2 (en) | 2014-12-11 | 2016-06-16 | Abbvie Inc. | Lrp-8 binding proteins |
| TW201710286A (zh) | 2015-06-15 | 2017-03-16 | 艾伯維有限公司 | 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白 |
| EP3353204B1 (en) | 2015-09-23 | 2023-10-18 | Mereo BioPharma 5, Inc. | Bi-specific anti-vegf/dll4 antibody for use in treating platinum-resistant ovarian cancer |
| WO2018094267A1 (en) * | 2016-11-17 | 2018-05-24 | Children's Medical Center Corporation | Novel methods to enhance microvascular engraftment of bioengineered and primary tissues |
| US20210278418A1 (en) * | 2018-03-15 | 2021-09-09 | The Chidlren's Medical Center Corporation | Method for treating asthma or allergic disease |
| EP3843798A1 (en) * | 2018-08-31 | 2021-07-07 | Wisconsin Alumni Research Foundation | Generating arterial endothelial cell-seeded vascular grafts |
| WO2020223610A1 (en) * | 2019-05-01 | 2020-11-05 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Engineering broadly reactive human notch ligands as novel tools for biomedical applications |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6303769B1 (en) | 1994-07-08 | 2001-10-16 | Immunex Corporation | Lerk-5 dna |
| EP0861261B9 (en) | 1995-06-28 | 2010-02-24 | Imperial Cancer Research Technology Limited | Nucleotide and protein sequences of vertebrate delta genes and methods based thereon |
| WO2002000690A2 (en) | 2000-06-23 | 2002-01-03 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis |
| EP0972041B2 (en) | 1997-04-04 | 2017-01-18 | Millennium Pharmaceuticals, Inc. | Novel human delta3 compositions and therapeutic and diagnostic uses therefor |
| US6121045A (en) | 1997-04-04 | 2000-09-19 | Millennium Biotherapeutics, Inc. | Human Delta3 nucleic acid molecules |
| JP4171528B2 (ja) | 1997-05-14 | 2008-10-22 | 旭化成株式会社 | 新規な分化抑制剤 |
| EP1100899A2 (en) | 1998-07-27 | 2001-05-23 | Amgen Inc. | Delta-related polypeptides |
| CA2367213A1 (en) | 1999-03-18 | 2000-09-21 | Children's Medical Center Corporation | Novel antiangiogenic peptides |
| CA2416538A1 (en) | 2000-07-20 | 2002-01-31 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis |
| JP4365583B2 (ja) | 2000-09-22 | 2009-11-18 | ジェネンテック・インコーポレーテッド | ノッチレセプターアゴニスト及び用途 |
| US6689744B2 (en) | 2000-09-22 | 2004-02-10 | Genentech, Inc. | Notch receptor agonists and uses |
| JP2005503792A (ja) | 2001-08-22 | 2005-02-10 | ガラパゴス・ジェノミックス・ナムローゼ・フェンノートシャップ | ハイ・スループット・スクリーニングにおいて同定される骨の恒常性のモジュレーター |
| CA2465304A1 (en) | 2001-11-14 | 2003-05-22 | Lorantis Limited | Composition comprising inhibitors of the notch signalling pathway for the modulation of the immune system |
| JP2006506322A (ja) | 2002-04-05 | 2006-02-23 | ロランティス リミテッド | 内科療法 |
| WO2004083372A2 (en) * | 2003-03-21 | 2004-09-30 | Lorantis Limited | Modulators of the notch signaling pathway immobilized on particles for modifying immune responses |
| ATE474593T1 (de) * | 2003-03-21 | 2010-08-15 | Celldex Therapeutics Ltd | Behandlung von allergischen erkrankungen unter verwendung eines modulators des notch signaling pathway |
| US7837993B2 (en) * | 2004-03-19 | 2010-11-23 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for regeneration of aged skeletal muscle tissues |
| US7888116B2 (en) * | 2004-07-22 | 2011-02-15 | The United States Of America As Represented By The Department Of Health And Human Services | Uses of notch receptors, notch ligands, and notch modulators in methods related to metabolic diseases |
| US7906116B2 (en) * | 2005-09-01 | 2011-03-15 | Parkash Gill | Methods for using and identifying modulators of Delta-like 4 |
| EP1928486A2 (en) | 2005-09-01 | 2008-06-11 | Vasgene Therapeutics, Inc. | Methods for using and identifying modulators of delta-like 4 |
| DK1962895T3 (da) * | 2005-12-16 | 2013-03-04 | Regeneron Pharma | TERAPEUTISK ANVENDELSE AF EN Dll4-ANTAGONIST OG EN VEGF-HÆMMER TIL HÆMNING AF TUMORVÆKST |
| KR20090016762A (ko) * | 2006-06-06 | 2009-02-17 | 제넨테크, 인크. | 혈관 발달을 조정하기 위한 조성물 및 방법 |
| KR20090027227A (ko) * | 2006-06-06 | 2009-03-16 | 제넨테크, 인크. | 항-ｄｌｌ4 항체 및 이의 사용 방법 |
| EA018260B1 (ru) * | 2006-09-29 | 2013-06-28 | Онкомед Фармасьютикалз, Инк. | Антитела к дельта-подобному лиганду 4 человека и их применение |
| NO347649B1 (no) * | 2006-12-14 | 2024-02-12 | Regeneron Pharma | Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse. |
| AU2007338734A1 (en) | 2006-12-20 | 2008-07-03 | Vasgene Therapeutics, Inc. | Methods for using and identifying modulators of delta-like 4 |
| EP2125887A4 (en) * | 2007-01-24 | 2010-11-10 | Oncomed Pharm Inc | COMPOSITIONS AND METHODS OF TREATMENT AND DIAGNOSIS OF CANCER |
-
2007
- 2007-12-20 US US12/005,054 patent/US7906116B2/en not_active Expired - Fee Related
-
2008
- 2008-12-19 CN CN2008801271728A patent/CN101970004A/zh active Pending
- 2008-12-19 WO PCT/US2008/013899 patent/WO2009085209A2/en not_active Ceased
- 2008-12-19 CA CA2710082A patent/CA2710082A1/en not_active Abandoned
- 2008-12-19 JP JP2010539496A patent/JP2011507852A/ja active Pending
-
2010
- 2010-06-20 IL IL206502A patent/IL206502A0/en unknown
-
2011
- 2011-02-04 US US13/021,617 patent/US20110213127A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011507852A5 (https=) | ||
| HRP20210848T1 (hr) | Sastavi i postupci za sprječavanje aktivnosti arginaze | |
| EP0719859B1 (en) | Anti-alpha V-integrin monoclonal antibody | |
| JP6429771B2 (ja) | ｃ−Ｍｅｔに結合する抗原結合タンパク質 | |
| JP2009528263A5 (https=) | ||
| HRP20201046T1 (hr) | Sastavi i metode za inhibitivnu aktivnost arginase | |
| BRPI0412478B8 (pt) | anticorpo que se liga ao igf-ir, composição farmacêutica e seu método de fabricação, linhagens celulares de hibridoma, ácido nucleico, vetor de expressão, célula hospedeira, 5 e métodos para a produção de um polipeptídeo que se liga ao igf-ir e inibe a ligação de igf-i e igf-ii ao igf-ir, e para a seleção de um anticorpo anti-igf-ir a partir de uma pluralidade de anticorpos anti-igf-ir | |
| TW201728340A (zh) | 包含肽基之結合物及與其相關之方法 | |
| AR068767A1 (es) | Anticuerpos contra esclerostina, composiciones y metodos de uso de estos anticuerpos para tratar un trastorno patologico mediado por esclerostina | |
| HRP20170110T1 (hr) | Monoklonska protutijela | |
| CN104854132A (zh) | Rspo3结合剂及其用途 | |
| IL302093B1 (en) | Combination therapy involving anti-claudin 18.2 antibodies for cancer treatment | |
| MX2009012732A (es) | Anticuerpos anti-trop-2 humanizados e hibridos que median citotoxicidad de celulas cancerosas. | |
| RU2007141588A (ru) | Наночастица, и на ее основе инфузионный раствор и фармацевтическая композици | |
| JPWO2019220368A5 (https=) | ||
| CN110325188A (zh) | 小分子蛋白质精氨酸甲基转移酶5(prmt5)抑制剂和治疗方法 | |
| RU2464041C2 (ru) | Применение антитела к cd151 для лечения рака | |
| BRPI0418765A (pt) | composto, composição farmacêutica, método de inibir o tgf-b, método de reduzir o acúmulo de excesso de matriz extracelular, método de inibir metástese de células tumorais, método de tratar carcinomas, método de tratar uma doença pró-droga, método de inibir trombose | |
| Tucker et al. | Revisiting the tenascins: exploitable as cancer targets? | |
| Marty et al. | Isolation and characterization of a scFv antibody specific for tumor endothelial marker 1 (TEM1), a new reagent for targeted tumor therapy | |
| US20210122818A1 (en) | Humanized anti-bag3 antibodies | |
| JP2020531430A (ja) | 抗体を標的とする抗ｃｔｌａ４プロボディ療法 | |
| US20190106484A1 (en) | Antibody against peptide encoded by exon-21 of periostin and pharmaceutical composition for preventing or treating inflammation-associated diseases containing the same | |
| JP2013541944A5 (https=) | ||
| WO2016207402A1 (en) | Proteins comprising a mutated lair-1 fragment and uses thereof |